RxDoctor Payments Data

Tsung Han Ching, MD

Internal Medicine · Odessa, TXNPI 1508351719

Payments from drug & device makers

$5,417in general payments, 2019–2025

Across 289 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$714
  • Amgen$714
  • Novo Nordisk$437
  • AbbVie$337
  • GSK$291
  • Merck$267
  • plus $3K from 33 others

What the payments were for

  • Travel & lodging$4558%
  • Food & beverage$4,95091%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,417 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$32,144
Medicare patients
85
Services billed
313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin59$71,731
EliquisApixaban55$46,795
LinzessLinaclotide40$38,765
OzempicSemaglutide36$35,487
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$25,604
MounjaroTirzepatide16$19,331
JanuviaSitagliptin Phosphate14$15,371
XareltoRivaroxaban12$15,018
MyrbetriqMirabegron26$11,577
TrulicityDulaglutide12$11,468
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$11,323
EntrestoSacubitril/Valsartan11$8,590
Breo ElliptaFluticasone/Vilanterol11$4,535
Fluticasone-VilanterolFluticasone/Vilanterol12$4,038
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$3,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$225$71,73159 claims
PfizerEliquis$131$46,79555 claims
AbbVieLinzess$337$38,76540 claims
Novo NordiskOzempic$437$35,48736 claims
Lilly USA, LLCMounjaro, Trulicity$260$30,79928 claims
GSKTrelegy Ellipta, Breo Ellipta$291$30,13945 claims
MerckJanuvia$267$15,37114 claims
Johnson & JohnsonXarelto$246$15,01812 claims
Astellas Pharma US IncMyrbetriq$33$11,57726 claims
NovartisEntresto$62$8,59011 claims
AstraZenecaSymbicort$242$3,32112 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$60$1,64790 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Odessa

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →